BTMD
$1.36
biote Corp.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormona...
Recent News
Biote Corp (BTMD) Q4 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges
Biote Corp (BTMD) focuses on expanding its sales force and enhancing technology, despite facing revenue and margin pressures.
biote Corp. Q4 2025 Earnings Call Summary
Moby summary of biote Corp.'s Q4 2025 earnings call
biote Q4 Earnings Call Highlights
biote (NASDAQ:BTMD) used its fourth-quarter and full-year 2025 earnings call to outline changes made over the past year to its commercial organization and operating model, while also detailing near-term financial pressure tied to procedure trends, planned investments, and a voluntary recall at its A
biote (BTMD) Q4 2025 Earnings Call Transcript
Before we get started, I would like to remind everyone that management statements during this call include forward-looking statements regarding, among other things, the company's financial results, future performance and growth opportunities, business outlook, strategic plans, anticipated benefits, goals, research and development, manufacturing and commercialization activities, its competitive position, regulatory process operations, benefits of its solutions, anticipated impact of macroeconomic conditions on the business, results of operations and financial conditions, and other matters that do not relate to historical facts. For discussion of risks and other important facts that could affect their actual results, please refer to our SEC filings available on the SEC's website and in the Investor Relations section of our website as well as risks and other important factors discussed in the earnings release.
biote Corp. (BTMD) Q4 Earnings and Revenues Top Estimates
biote Corp. (BTMD) delivered earnings and revenue surprises of +20.00% and +1.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?